Robert Avery is an Oncology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
645 Mcqueen Smith Rd N Ste 207
Prattville, AL 36066
Telephone
334-351-1000Provider last certified this registry record 18 Jul 2023.
Clinical trials
- Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)
Sponsor: California Retina Consultants
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Sponsor: California Retina Consultants
- Analysis of Aqueous and Vitreous Humor
Sponsor: California Retina Consultants
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
78 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202518 payments
- Novartis Pharmaceuticals CorporationProgram year202513 payments
- ABBVIE INC.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
28%Opioid Agonist9.7%Oxycodone-Acetaminophen42%Oxycodone Hcl15%Tramadol Hcl14%Hydromorphone Hcl11%Morphine Sulfate7%Fentanyl6%Oxycontin6%Part D<11 patientsPhenothiazine6.2%Prochlorperazine Maleate72%Compro28%Part D≥63 patients+ 8 more classes in this area
Cancer & immunology
20.2%Aromatase Inhibitor5.7%Anastrozole80%Letrozole12%Exemestane8%Part D<11 patientsKinase inhibitor5.2%Jakafi28%Imbruvica19%Verzenio12%Iclusig11%Kisqali11%Bosulif10%Imatinib Mesylate10%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
12.8%Serotonin-3 Receptor Antagonist5.3%Ondansetron Odt100%Part D≥76 patientsCorticosteroid5%Prednisone100%Part D≥35 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”